Neurocrine Biosciences (NBIX) Amortization of Deferred Charges (2017 - 2023)

Neurocrine Biosciences has reported Amortization of Deferred Charges for 7 years, with the latest figure at $100000.0 in Q4 2023.

• For the quarter ending Q4 2023, Amortization of Deferred Charges fell 50.0% year-over-year to $100000.0; the trailing twelve-month figure through Dec 2023 stood at $700000.0 (down 41.67% YoY), and the FY2023 full-year result was $700000.0, down 41.67% from the prior year.
• Amortization of Deferred Charges for Q4 2023 stood at $100000.0, down from $200000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $400000.0 in Q2 2019, with the low at $100000.0 in Q4 2023.
• Historically, Amortization of Deferred Charges has averaged $290000.0 across 5 years, with a median of $300000.0 in 2019.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 33.33% — and 2023, when it sank 50.0%.
• Neurocrine Biosciences' Amortization of Deferred Charges stood at $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then retreated by 25.0% to $300000.0 in 2021, then plunged by 33.33% to $200000.0 in 2022, then slumped by 50.0% to $100000.0 in 2023.
• The last three Amortization of Deferred Charges figures came in at $100000.0 (Q4 2023), $200000.0 (Q3 2023), and $200000.0 (Q2 2023), per Business Quant data.